CYCLE CONTROL WITH DESOGESTREL-CONTAINING ORAL-CONTRACEPTIVES - COMPARISON OF A MONOPHASIC AND TRIPHASIC REGIMEN

被引:0
|
作者
CARR, BR
机构
关键词
DESOGESTREL; COMBINED ORAL CONTRACEPTIVES (OCS); MONOPHASIC; TRIPHASIC; CYCLE CONTROL; BREAKTHROUGH BLEEDING; SPOTTING; WITHDRAWAL BLEEDING;
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective-To examine the effect of mono- and triphasic desogestrel-containing oral contraceptives on cycle control. Setting-Multicenter, international (U.S. and Canada). Patients and Interventions-About 4,000 women, aged 18-35, healthy, neither pregnant nor lactating, were followed for almost 37,700 cycles of use of a monophasic 150 mug desogestrel/30 mug ethinyl estradiol OC or Sunday- or day-1 start regimens of a triphasic preparation containing 50/100/150 mug desogestrel/35/30/30 mug ethinyl estradiol administered on a 7/7/7 schedule. Standard diary methods were used to collect data on breakthrough bleeding, spotting, and absence of withdrawal bleeding. Results-The two formulations demonstrated very low and, in fact, remarkably similar rates of breakthrough bleeding, spotting, and absence of withdrawal bleeding. A statistical analysis of these characteristics of the total study populations, per cycle, revealed no statistically significant differences between the formulations. Conclusion-Although the triphasic formulation contains the lowest estrogen dose of any triphasic available, 33% less progestin than the monophasic formulation, it maintains comparable cycle control.
引用
收藏
页码:274 / 279
页数:6
相关论文
共 50 条
  • [1] A comparison of cycle control and effect on well-being of monophasic gestodene-, triphasic gestodene- and monophasic desogestrel-containing oral contraceptives
    Bruni, V
    Croxatto, H
    De la Cruz, J
    Dhont, M
    Durlot, F
    Fernands, MTMS
    Andrade, RP
    Weisberg, E
    Rhoa, M
    GYNECOLOGICAL ENDOCRINOLOGY, 2000, 14 (02) : 90 - 98
  • [2] DESOGESTREL-CONTAINING ORAL-CONTRACEPTIVES AND BLOOD-PRESSURE
    DIEBEN, TOM
    VANBEEK, A
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1986, 36-2 (11): : 1678 - 1680
  • [3] LIPID-METABOLISM EFFECTS WITH DESOGESTREL-CONTAINING ORAL-CONTRACEPTIVES
    BURKMAN, RT
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1993, 168 (03) : 1033 - 1040
  • [4] ESTROGENIC EFFECT OF GESTODENE-CONTAINING OR DESOGESTREL-CONTAINING ORAL-CONTRACEPTIVES ON LIPOPROTEIN METABOLISM
    LEUVEN, JAG
    DERSJANTROORDA, MC
    HELMERHORST, FM
    DEBOER, R
    NEYMEYERLELOUX, A
    HAVEKES, L
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1990, 163 (01) : 358 - 362
  • [5] ORAL-CONTRACEPTIVES IN PREMENSTRUAL-SYNDROME - A RANDOMIZED COMPARISON OF TRIPHASIC AND MONOPHASIC PREPARATIONS
    BACKSTROM, T
    HANSSONMALMSTROM, Y
    LINDHE, BA
    CAVALLIBJORKMAN, B
    NORDENSTROM, S
    CONTRACEPTION, 1992, 46 (03) : 253 - 268
  • [6] SELECTIVITY AND MINIMAL ANDROGENICITY OF NORGESTIMATE IN MONOPHASIC AND TRIPHASIC ORAL-CONTRACEPTIVES
    ANDERSON, FD
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1992, 71 : 15 - 21
  • [7] THE EFFECTS ON HEMOSTASIS OF ORAL-CONTRACEPTIVES CONTAINING DESOGESTREL
    STUBBLEFIELD, PG
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1993, 168 (03) : 1047 - 1052
  • [8] TRIPHASIC ORAL-CONTRACEPTIVES
    ALLEN, HH
    CONTRACEPTIVE DELIVERY SYSTEMS, 1982, 3 (3-4) : 108 - 108
  • [9] TRIPHASIC ORAL-CONTRACEPTIVES
    不详
    LANCET, 1981, 1 (8231): : 1191 - 1192
  • [10] FUNCTIONAL OVARIAN CYSTS IN RELATION TO THE USE OF MONOPHASIC AND TRIPHASIC ORAL-CONTRACEPTIVES
    HOLT, VL
    DALING, JR
    MCKNIGHT, B
    MOORE, D
    STERGACHIS, A
    WEISS, NS
    OBSTETRICS AND GYNECOLOGY, 1992, 79 (04): : 529 - 533